![](https://i.imgur.com/CLvY2jA.png")
13-08-2021, 07:56 PM
The vaccine – based on a self-assembling protein nanoparticle that displays 60 copies of the SARS-CoV-2 spike protein – is formulated with GlaxoSmithKline’s vaccine adjuvant, designed to boost the immune response.
The new phase 3 trial will involve 3,990 patients, 3,000 of whom will get two doses of GB510 while 990 will received two doses of Vaxzevria, both given four weeks apart.
The trial is thought to be the second comparative study for coronavirus vaccines after Valneva’s 4,000-patient Cov-Compare trial, which is pitting its adjuvanted, inactivated whole virus vaccine VLA2001 against the AZ shot.
https://pharmaphorum.com/news/sk-bios-co...us-az-jab/
The new phase 3 trial will involve 3,990 patients, 3,000 of whom will get two doses of GB510 while 990 will received two doses of Vaxzevria, both given four weeks apart.
The trial is thought to be the second comparative study for coronavirus vaccines after Valneva’s 4,000-patient Cov-Compare trial, which is pitting its adjuvanted, inactivated whole virus vaccine VLA2001 against the AZ shot.
https://pharmaphorum.com/news/sk-bios-co...us-az-jab/
